MOG/Myelin Oligodendrocyte Glyco, His, Human
MOG/Myelin Oligodendrocyte Glyco, His, Human

The purity of MOG/Myelin Oligodendrocyte Glyco, His, Human is greater than 95% as determined by SEC-HPLC.

MOG/Myelin Oligodendrocyte Glyco, His, Human

MOG/Myelin Oligodendrocyte Glyco, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

MOG/Myelin Oligodendrocyte Glyco, His, Human

Myelin oligodendrocyte glycoprotein (MOG) antibody disease is a rare autoimmune disorder with antibodies against the MOG predominantly involving the optic nerve and spinal cord leading to vision loss and paralysis. When MOG antibody disease involves the brain, the phenotype is similar to acute disseminated encephalomyelitis (ADEM).
Z05657
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
MOG/Myelin Oligodendrocyte Glycoprotein (Gly30-Gly154)_x000D_
Accession # Q16653		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 15.4 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 20-23 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • MOG/Myelin Oligodendrocyte Glyco, His, Human
    • MOG/Myelin Oligodendrocyte Glyco, His, Human

    The purity of MOG/Myelin Oligodendrocyte Glyco, His, Human is greater than 95% as determined by SEC-HPLC.

  • MOG/Myelin Oligodendrocyte Glyco, His, Human
    • MOG/Myelin Oligodendrocyte Glyco, His, Human

    MOG/Myelin Oligodendrocyte Glyco, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Myelin oligodendrocyte glycoprotein (MOG) antibody disease is a rare autoimmune disorder with antibodies against the MOG predominantly involving the optic nerve and spinal cord leading to vision loss and paralysis. When MOG antibody disease involves the brain, the phenotype is similar to acute disseminated encephalomyelitis (ADEM).
Synonyms MOG; MGC26137; MOG Ig-AluB; MOGIG2; BTN6; BTNL11; NRCLP7

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.